We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for apalutamide (Janssen-Cilag Pty Ltd)
Active ingredients
apalutamide
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Dosage form(s)
Tablet
Indication
For the treatment of patients with castration-resistant prostate cancer at risk of developing metastases
Registration date